Photo by: Nathana Rebouças on Unsplash

Novo Holdings Acquires U.S. Pharmaceutical Manufacturer Catalent

Novo Holdings has completed the acquisition of the U.S. pharmaceutical manufacturer Catalent in a deal valued at $16.5 billion. With all regulatory closing conditions met, this acquisition represents a significant achievement for both companies.

Expanding Global Reach in Pharmaceuticals

As a key player in life sciences investment globally, Novo Holdings has significantly expanded its presence in the pharmaceutical industry through this deal. The acquisition also involves the transfer of three facilities to Novo Nordisk for $11 billion, following the green light from the Federal Trade Commission (FTC).

During the successful acquisition process, Novo Nordisk’s position in the market has substantially strengthened. The FTC’s approval of the Novo-Catalent deal is a pivotal moment for Novo Nordisk, solidifying its standing in the industry.